Food and Drug Administration (FDA) approval of TAVNEOS in October 2021.

Dasatinib-induced ERK activation was completely abolished by exposure to the FDA-approved MEK inhibitor The results provide rationale for considering a combination(s) of FDA-approved SFK (dasatinib) and MEK

January 2022 "After securing FDA approval for Wegovy last year, Novo Nordisk is strengthening its position

Eosinophilic esophagitis , Eosinophilic granulomatosis with polyangiitis , European Medicines Agency , FDA

experience as a Clinical Research Associate at IQVIA and regulatory officer at the Food and Drug Authority (FDA